In an announcement made on 25 August, the pharmaceutical company Novartis said experimental medication siponimod was able to reduce the risk of disability progression in people with secondary progressive MS.read more
Ocrelizumab (trading as Ocrevus) had been submitted to the pharmaceutical regulators in the US and Europe, but in news closer to home, Roche has also announced that ocrelizumab has also…read more
MS Research Australia’s landmark PrevANZ vitamin D MS prevention trial is continuing to make steady progress, and has reached the exciting milestone of 100 patients enrolled in the trial towards…read more
Professor Anne La Flamme and Dr David Abernethy are conducting a clinical trial in Wellington to examine the use of two medicines, clozapine and risperidone, for the treatment of multiple…read more
The results of a Phase II clinical trial looking at the effects of a new therapy, ozanimod,for relapsing MS has been published in the journal Lancet Neurology.read more
